UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program

加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划

• 批准号: 10681247
• 负责人: PRIMO N. LARA
• 金额: $ 73.47万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10681247
• 关键词: Automobile Driving; Basic Science; Cancer Patient; Center for Translational Science Activities; Clinical; Clinical Oncology Supplement (K12); Clinical Research; Clinical Skills; Clinical Trials; Communication; Competence; Comprehensive Cancer Center; Development; Discipline; Ensure; Environment; Ethics; Evaluation; Faculty; FarGo; Funding; Goals; Grant; Infrastructure; Language; Malignant Neoplasms; Mentored Clinical Scientist Development Program; Mentors; Mentorship; National Center for Advancing Translational Sciences; Oncology; Patients; Physicians; Program Development; Research; Research Design; Research Personnel; Research Project Grants; Research Training; Scholars Program; Science; Scientist; Time; Training; Translational Research; Vision; Writing; cancer clinical trial; career; career development; clinical investigation; didactic education; drug development; drug discovery; evidence base; improved outcome; innovation; interest; medical schools; multidisciplinary; patient oriented; patient oriented research; programs; research and development; skills; success; translational scientist

PROJECT SUMMARY The overarching goal of the UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program (CDP) is to nurture clinician or basic/translational junior faculty to become independent, patient- oriented cancer researchers who are highly trained in translational, team-driven research. Using 1) core competencies, 2) advanced oncology coursework, 3) career development, 4) mentored research, and 5) cross- discipline exposure, the CDP provides two new scholars per year (six at any one time) a three-year career development program aimed at honing ideas and skills that go far beyond their initial disciplinary boundaries. Scholars will overcome language and cultural barriers that typically exist between clinical and basic/translational researchers, take advantage of the collaborative research environment at UC Davis, participate in multidisciplinary and translational forums, and gather essential skills in research design, clinical trial development, team science, grant writing, ethical conduct of research, communication, and career development. The vision is to enhance translational research by training physician-scientists to incorporate and utilize basic/correlative science in their pursuit of clinical trials ("Clinical Track"), and conversely, driving basic scientists towards patient-driven drug development and clinical research ("Basic/Translational Track"). To maintain the emphasis on patient-driven clinical research, CDP scholars, under the mentorship of both a clinical mentor and basic/translational mentor, will be required to develop and initiate/conduct their own investigator-initiated clinical trial during the training period. The program will leverage the outstanding research, training, and evaluation expertise and infrastructure of the NCI-designated UC Davis Comprehensive Cancer Center, NCATS-funded Clinical and Translational Research Center (CTSC), and School of Medicine Career Development Program. It will be overseen and enhanced by a highly organized internal Oversight Committee and external Advisory Board. Overall, the CDP seeks to accomplish the following specific aims: 1) Offer a competency-based didactic curriculum to promote team science, encourage translational research, and hone essential skills for clinical trial development and career/research success; 2) Oversee individualized patient- oriented research projects customized to the interests and needs of each scholar; and 3) Provide oversight of scholar training to ensure the progressive development of fully competent interdisciplinary researchers who can successfully conduct cancer clinical trials. These specific aims will build a critical mass of trained scientists at the forefront of innovative, impactful, evidence-based research, who can oversee projects encompassing the entire continuum of research from basic science (target identification and drug discovery) through translational science (drug development and correlative science) to clinical investigation. By doing so, we offer the potential of enhancing the success of clinician scientists and improving outcomes for cancer patients.

项目摘要 UC Davis Paul Calabresi K12临床肿瘤学研究职业发展的总体目标 计划（CDP）是培养临床医生或基础/翻译初级教师成为独立的，病人- 面向癌症研究人员，他们在翻译，团队驱动的研究方面训练有素。使用1）核心 能力，2）高级肿瘤学课程，3）职业发展，4）指导研究，5）交叉 学科曝光，CDP每年提供两名新学者（任何时候六名），为期三年的职业生涯 发展计划，旨在磨练思想和技能，远远超出了他们最初的学科界限。 学者将克服语言和文化障碍，通常存在于临床和 基础/翻译研究人员，利用加州大学戴维斯分校的合作研究环境， 参加多学科和翻译论坛，并收集研究设计，临床 试验开发，团队科学，资助写作，研究道德行为，沟通和职业生涯 发展其愿景是通过培训医生科学家来加强转化研究， 利用基础/相关科学进行临床试验（“临床跟踪”），反之， 为科学家们提供了一个以患者为导向的药物开发和临床研究（“基础/转化轨道”）。到 保持对患者驱动的临床研究的重视，CDP学者，在双方的指导下， 临床导师和基础/翻译导师，将需要开发和启动/进行自己的 在培训期间进行的临床试验。该计划将利用杰出的研究， 培训和评估NCI指定的UC Davis综合癌症的专业知识和基础设施 中心，NCATS资助的临床和转化研究中心（CTSC），以及医学院 发展计划。它将由一个组织严密的内部监督委员会监督和加强 外部咨询委员会。总体而言，CDP寻求实现以下具体目标：1）提供 以能力为基础的教学课程，以促进团队科学，鼓励转化研究，并磨练 临床试验开发和职业/研究成功的基本技能; 2）监督个体化患者- 根据每个学者的兴趣和需求定制的研究项目; 3）提供监督 学者培训，以确保逐步发展完全胜任的跨学科研究人员， 可以成功地进行癌症临床试验。这些具体的目标将培养一批训练有素的科学家 在创新的，有影响力的，基于证据的研究的前沿，谁可以监督项目，包括 从基础科学（目标识别和药物发现）到转化的整个研究连续体 科学（药物开发和相关科学）到临床研究。通过这样做，我们提供了潜在的 提高临床科学家的成功和改善癌症患者的结果。

项目成果

MDS prognostic scoring systems – past, present, and future.

• DOI: 10.1016/j.beha.2014.11.001
• 发表时间: 2015-03
• 期刊: BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
• 影响因子: 2.1
• 作者: Jonas, Brian A.;Greenberg, Peter L.
• 通讯作者: Greenberg, Peter L.

Methods for Scarless, Selection-Free Generation of Human Cells and Allele-Specific Functional Analysis of Disease-Associated SNPs and Variants of Uncertain Significance.

• DOI: 10.1038/s41598-017-15407-4
• 发表时间: 2017-11-08
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Coggins NB;Stultz J;O'Geen H;Carvajal-Carmona LG;Segal DJ
• 通讯作者: Segal DJ

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.

• DOI: 10.1126/scitranslmed.aan2781
• 发表时间: 2017-04-19
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Jonas BA

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.

• DOI: 10.1097/cad.0b013e3283618b7b
• 发表时间: 2013-07
• 期刊: Anti-cancer drugs
• 影响因子: 2.3
• 作者: Semrad TJ;Eddings C;Dutia MP;Christensen S;Lara PN Jr
• 通讯作者: Lara PN Jr

Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.

• DOI: 10.2217/cns-2021-0005
• 发表时间: 2022-03-01
• 期刊: CNS oncology
• 作者: Aboud O;Shah R;Vera E;Burton E;Theeler B;Wu J;Boris L;Quezado M;Reyes J;Wall K;R Gilbert M;S Armstrong T;Penas-Prado M
• 通讯作者: Penas-Prado M